Life Science Investing Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Life Science Investing Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
